Английская Википедия:18-Methylsegesterone acetate
Шаблон:Short description Шаблон:Drugbox
18-Methylsegesterone acetate (18-methyl-SGA; also known as 18-methylnestorone) is a progestin medication of the 19-norprogesterone group which was never marketed.[1][2][3] It was first described in a patent in 1997 and then in a literature paper in 2003.[4][1] 18-Methyl-SGA is the C18 methyl or C13β ethyl derivative of segesterone acetate (SGA; 16-methylene-17α-acetoxy-19-norprogesterone), and shows 3 to 10 times the progestogenic potency of SGA in bioassays.[1] This is analogous to the case of the 19-nortestosterone progestin norethisterone and its 18-methyl derivative levonorgestrel, the latter showing substantially increased potency relative to the former similarly.[1] As SGA is already one of the most potent progestins to have been developed, with 100-fold the potency of progesterone and 10-fold the potency of levonorgestrel in bioassays, 18-methyl-SGA is an extremely potent progestogen, among if not the most potent known.[2][5][1]
SGA is a highly selective progestogen.[1][5] Like SGA, 18-methyl-SGA shows negligible affinity for the androgen receptor.[1][3] While 18-methyl-SGA has not been assessed at the other steroid hormone receptors, it is expected to be highly selective for the progesterone receptor similarly to SGA.[1] 18-Methyl-SGA shows over 16 times the affinity of progesterone for the progesterone receptor expressed in rat uterus.[1] In terms of oral bioavailability, it is known that SGA is not active orally, while the oral activity of 18-methyl-SGA is unknown.[1] The addition of an 18-methyl group to SGA is unlikely to affect its rate of delivery from sustained release systems.[1] As such, 18-methyl-SGA should be ideally suited for use via routes of administration like subcutaneous implants and transdermal patches.[1]
| Progestogen | Шаблон:Abbrlink Шаблон:Abbrlink (rat uterus) |
Clauberg assaya |
Pregnancy maintenance |
|---|---|---|---|
| 18-Methyl-SGA | 355% | 0.3 μg | 0.03 mg |
| Segesterone acetate | 107% | 1 μg | 0.3 mg |
| Levonorgestrel | 100% | 3 μg | 0.3 mg |
| Progesterone | 22% | 100 μg | 1.0 mg |
| Footnotes: a = Minimum effective dose. Sources: [1] | |||
See also
References
Шаблон:Progesterone receptor modulators
Шаблон:Steroid-stub
Шаблон:Genito-urinary-drug-stub
- ↑ 1,00 1,01 1,02 1,03 1,04 1,05 1,06 1,07 1,08 1,09 1,10 1,11 1,12 Шаблон:Cite journal
- ↑ 2,0 2,1 Шаблон:Cite journal
- ↑ 3,0 3,1 Шаблон:Cite journal
- ↑ 18-methyl 16-methylene 19-nor pregnane derivatives as progestins, pharmaceutical compositions containing them and process for the preparation thereof. https://patents.google.com/patent/WO1997023498A1/en
- ↑ 5,0 5,1 Шаблон:Cite journal
